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ANCA-associated Vasculitis:
Diagnostic and Therapeutic Strategy
Shoichi Ozaki1
ABSTRACT
Among small-vessel vasculitides, microscopic polyangiitis (MPA), Wegener’s granulomatosis (WG), and aller-
gic granulomatous angiitis (AGA) are known collectively as ANCA-associated vasculitis (AAV) because of the
involvement of anti-neutrophil cytoplasmic antibodies (ANCA) as the common pathogenesis. Major target anti-
gens of ANCA associated with vasculitis are myeloperoxidase (MPO) and proteinase 3 (PR3). MPO-ANCA is
related to MPA and AGA, and PR3-ANCA is the marker antibody in WG. MPO-ANCA-associated vasculitis is
more frequent in Japan, whereas PR3-ANCA-associated vasculitis is more common in Europe and USA.
ANCA appears to induce vasculitis by directly activating neutrophils. Therefore, no immunoglobulins or comple-
ment components are detected in the vasculitis lesions; hence, AAV is called pauci-immune vasculitis (pauci =
fewlittle). Untreated patients with severe AAV with multi-organ involvement have a poor prognosis, which is
improved by combination therapy with cyclophosphamide and high-dose corticosteroid. Randomized controlled
trials (RCT) regarding induction and maintenance of remission of AAV indicated that the rate of remission in-
duction by the standard regimen is approximately 90% in 6 months, that maintenance of remission can be
achieved with oral azathioprine as well as cyclophosphamide, and that methotrexate can be used only for non-
renal mild AAV. As these data were obtained mostly in patients positive for PR3-ANCA, caution must be taken
in applying these findings to Japanese patients, most of whom are positive for MPO-ANCA. A prospective
study is now underway to clarify the effectiveness of the standard regimen in Japanese patients with MPO-
ANCA-associated vasculitis. This article describes the diagnostic criteria and the recent evidence-based thera-
peutic strategy of AAV.
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INTRODUCTION
Vasculitis is defined as inflammation of the vessel
walls. Vasculitis develops either primarily or secon-
dary to certain background conditions, such as infec-
tion, malignancy, and systemic rheumatic diseases.
Primary vasculitis has been classified based on the
size of the affected vessels (International Consensus
Conference, 1994). Thus, large-vessel vasculitis in-
cludes Takayasu’s arteritis and temporal arteritis (gi-
ant cell arteritis), medium sized-vessel vasculitis in-
cludes polyarteritis nodosa (PN) and Kawasaki’s dis-
ease, and small-vessel vasculitis includes microscopic
polyangiitis (MPA), Wegener’s granulomatosis (WG),
allergic granulomatous angiitis (AGA), Henoch-
Schönlein purpura, essential cryoglobulinemic pur-
pura, and cutaneous leukocytocrastic vasculitis.1
Among the types of small-vessel vasculitis, MPA,
WG, and AGA are separated from the classical PN,
and have common characteristics: the affected ves-
sels are arterioles, capillaries, and venules; the most
common organs affected are the kidney and lung;
they involve anti-neutrophil cytoplasmic antibody
(ANCA) as the common pathogenesis.2 Therefore,
MPA, WG, and AGA are called ANCA-associated vas-
culitis (AAV). ANCA can be detected by indirect im-
munofluorescence using ethanol-fixed neutrophils.
Two staining patterns are known, perinuclear (P-
ANCA) and cytoplasmic (C-ANCA). The major target
antigen of P-ANCA associated with vasculitis is
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Table 1 Diagnostic criteria for microscopic polyangitis 
(MPA)
1. Symptoms
(1) Rapidly progressive glomerulonephritis
(2) Pulmonary hemorhage
(3) Other organ symptoms:
Purpura, subcutaneous hemorhage, gastrointestinal 
bleeding, and mononeuritis multiplex
2. Histological findings
(1) Necrotizing vasculitis of arterioles, capilaries, and ve-
nules, and perivascular infiltration of inflammatory cels
3. Laboratory findings
(1) Positive MPO-ANCA
(2) Positive CRP
(3) Proteinuria, hematuria, elevation of BUN and serum 
creatinine
<Diagnosis>
1. Definite MPA
(1) Positive for 2 or more of the symptoms, and positive 
histological findings
(2) Positive for 2 or more of the symptoms including the 
symptoms (1) and (2), and positive MPO-ANCA
2. Probable MPA
(1) Positive for 3 of the symptoms
(2) Positive for 1 of the symptoms, and positive MPO-
ANCA
From the Research Group of Intractable Vasculitis, MHLW of 
Japan (1998) 7
myeloperoxidase (MPO),3 while that of C-ANCA is
proteinase 3 (PR3).4 MPO-ANCA is related to MPA
and AGA, and PR3-ANCA is the marker antibody in
WG. In Japan, MPO-ANCA-associated vasculitis is
more frequent than PR3-ANCA-associated vasculitis,
whereas PR3-ANCA-associated vasculitis is much
more common in Europe. The mechanism of the de-
velopment of AAV involves the activation of neutro-
phils by ANCA.5,6 Therefore, no immunoglobulins or
complement components are detected in the vasculi-
tis lesions, and hence AAV is called pauci-immune
vasculitis (pauci = few or little).
This article mainly describes the therapeutic strat-
egy for AAV.
DIAGNOSIS AND EVALUATION OF AAV
Due to the high toxicity of cyclophosphamide, one of
the standard regimens for AAV, a precise and definite
diagnosis is required before treating patients with
AAV. Diagnostic criteria have been reported by the
Research Group of Intractable Vasculitis, Ministry of
Health, Labor, and Welfare (MHLW) of Japan.7-9
Renal and pulmonary symptoms are characteristic
in microscopic polyangiitis (MPA), and interstitial
pneumonitis and pulmonary hemorrhage are com-
mon. MPO-ANCA is positive at a rate of 50―75%. Bi-
opsy of the involved organs reveals necrotizing cres-
centic glomerulonephritis and necrotizing vasculitis
of arterioles, capillaries, and venules with few im-
mune deposits. The diagnostic criteria of the Japa-
nese Research Group, MHLW, for MPA7 are listed in
Table 1. Granulomatous inflammation and asthma are
not seen in MPA.10
Wegener’s granulomatosis (WG) is differentiated
from MPA by the presence of necrotizing granuloma-
tous inflammation.10 These lesions preferentially af-
fect the ear, nose and throat (E), lung (L), and kidney
(K). The E symptoms include nasal symptoms (puru-
lent rhinorrhea, epistaxis, and a saddle nose), eye
symptoms (ophthalmic pain, visual disturbance, and
exophthalmia), ear symptoms (otalgia and otitis me-
dia), and throat symptoms (pharyngeal ulcer, hoarse-
ness, and laryngeal obstruction). The L symptoms in-
clude bloody sputa, cough, and dyspnea, and the K
symptoms include hematuria, proteinuria, rapidly
progressive renal failure, edema, and hypertension.
PR3-ANCA is positive at >90%. Biopsies of the nasal
mucosa, lung, and kidney reveal necrotizing granulo-
matous vasculitis and necrotizing crescentic glomeru-
lonephritis without immune deposits. WG with all of
the E, L, and K involvement is classified as the gener-
alized form, while that without K involvement (i.e., E
only, L only, or E + L) is classified as a limited form.
The therapeutic strategies are different for each form.
The diagnostic criteria of the Japanese Research
Group, MHLW, for WG8 are shown in Table 2.
Allergic granulomatous angiitis (AGA) was first de-
scribed by Churg and Strauss.11 AGA can be differen-
tiated from the other two diseases by the presence of
asthma, eosinophilia, and necrotizing granulomatous
inflammation.10 Within several years after the onset
of asthma, manifestations of small-vessel vasculitis
develop, such as palpable purpura of the lower ex-
tremities, mononeuritis multiplex, abdominal pain,
and gastrointestinal bleeding. Eosinophilia and posi-
tive MPO-ANCA are seen. Skin biopsy reveals ne-
crotizing vasculitis of small vessels with massive
eosinophilic infiltration and extravascular granuloma-
tosis. The diagnostic criteria of the Japanese Re-
search Group, MHLW, for AGA9 are shown in Table
3. According to the Research Group, patients with
definite histological findings are classified as AGA,
whereas those with a typical clinical course, but lack-
ing histological findings, are classified as Churg-
Strauss syndrome.
In addition to the precise diagnosis, evaluation of
the extent of organ involvement is also important be-
cause it determines which therapeutic strategy
should be chosen. The Birmingham Vasculitis Activ-
ity Index (BVAS)12 is employed for evaluation of the
activity of vasculitis, and the Vasculitis Damage Index
(VDI)13 for analysis of organ damage.
THERAPEUTIC STRATEGY OF AAV: GLO-
BAL EVIDENCE
Untreated patients with severe WG with multi-organ
ANCA-associated Vasculitis
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Table 2 Diagnostic criteria for Wegener’ sgranulomatosis (WG)
1. Symptoms
(1) E symptoms
Nose (purulent rhinorhea, epistaxis, and saddle nose)
Eyes (ophthalmic pain, visual disturbance, and exophthalmia)
Ears (otalgia and otitis media)
Throat (pharyngeal ulcer, hoarseness, and laryngeal obstruction)
(2) L symptoms
Bloody sputa, cough, and dyspnea
(3) K symptoms
Hematuria, proteinuria, rapidly progressive renal failure, edema, and hypertension
(4) Others due to vasculitis
(a) General symptoms: fever (38°C or higher, 2 weeks or longer), weight loss (6 kg or more for 6 months)
(b) Local symptoms: purpura, polyarthritis/polyarthralgia, episcleritis, mononeuritis multiplex, ischemic heart disease, gas-
trointestinal bleeding, and pleuritis
2. Histological findings
(1) Necrotizing granulomatous vasculitis with giant cels at the sites of E, L, and/or K
(2) Necrotizing crescentic glomerulonephritis without immune deposits
(3) Necrotizing granulomatous vasculitis of arterioles, capilaries, and venules
3. Laboratory findings
(1) Positive PR3-ANCA (or C-ANCA by an indirect immunofluorescence)
<Diagnosis>
1. Definite WG
(1) Positive for 3 or more of the symptoms, including E, L, and K symptoms
(2) Positive for 2 or more of the symptoms, and positive for either of the histological findings
(3) Positive for 1 or more of the symptoms, positive for either of the histological findings, and positive PR3-ANCA/C-ANCA
2. Probable WG
(1) Positive for 2 or more of the symptoms
(2) Positive for 1 of the symptoms, and positive for either of the histological findings
(3) Positive for 1 of the symptoms, and positive PR3-ANCA/C-ANCA
From the Research Group of Intractable Vasculitis, MHLW of Japan (1998) 8
involvement have a poor prognosis with up to 90% of
patients dying within 2 years.14 Combination therapy
with cyclophosphamide and high-dose corticosteroid,
however, induces improvement in >90% of patients
with WG and complete remission in 75%.14 With re-
gard to the induction and maintenance of remission
of AAV, 3 randomized controlled trials (RCT) have
been reported as summarized in Table 4 .15-17
CYCAZAREM
This RCT, performed in Europe, compared the effec-
tiveness of cyclophosphamide (CYC) and azathio-
prine (AZA) in maintenance of remission (REM).15
This study included 155 patients (95 with WG, 60
with MPA), who achieved remission after induction
therapy with oral cyclophosphamide (2 mgkgday)
plus prednisolone (initial 1 mgkgday, tapered to
0.25 mgkgday by 12 weeks). The rate of induction
of remission was 93% in 6 months. The patients were
assigned randomly to either continued cyclophos-
phamide (1.5 mgkgday; n = 73) or azathioprine (2
mgkgday; n = 71) ; prednisolone (10 mgday) was
also given in each regimen. At one year, both groups
were given azathioprine (1.5 mgkgday) plus pred-
nisolone (7.5 mgday).
At 18-month follow-up, the rates of relapse were not
significantly different between the two groups (16%
vs. 14% in the azathioprine and cyclophosphamide
groups, respectively). During the remission phase,
both groups had a similar number of severe adverse
events. In contrast, a significant difference in the
rates of relapse was observed between WG and MPA
(18% vs. 8%, respectively, P = 0.03). Thus, this study
clearly showed that maintenance of remission can
also be achieved with oral azathioprine.
WGET
The Wegener’s Granulomatosis Etanercept Trial
(WGET) was performed in the USA.16 This well-
designed study of 180 patients with WG (128 with the
generalized form; 52 with a limited form) evaluated
the effectiveness of etanercept vs. placebo to enhance
the ability of standard therapy to maintain remission.
Patients were assigned randomly to either etanercept
(25 mg, subcutaneous injection, twice a week) or pla-
cebo groups. Standard therapy was also given in each
Ozaki S
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Table 3 Diagnostic criteria for alergic granulomatous angitis (AGA) (Churg-Strauss syndrome)
1. Symptoms
(1) Bronchial asthma and/or alergic rhinitis
(2) Eosinophilia
(3) Symptoms due to vasculitis
(a) General symptoms: fever (38°C or higher, 2 weeks or longer), weight loss (6 kg or more for 6 months)
(b) Local symptoms: mononeuritis multiplex, gastrointestinal bleeding, purpura, polyarthritis/polyarthralgia, and myalgia 
(muscle weakness)
2. Characteristic clinical course
(1) Symptoms (1) and (2) precede the development of (3)
3. Histological findings
(1) Granulomatous or necrotizing vasculitis of smal vessels with marked infiltration of eosinophils
(2) Extravascular granulomas
<Diagnosis>
1. Definite
(1) Positive for 1 or more of the symptoms (1) and (2), and positive for either of the histological findings (Definite AGA)
(2) Positive for 3 of the symptoms, and the characteristic clinical course (Definite Churg-Strauss syndrome)
2. Probable
(1) Positive for 1 of the symptoms, and positive for either of the histological findings (Probable AGA)
(2) Positive for 3 of the symptoms, but not the characteristic clinical course (Probable Churg-Strauss syndrome)
From the Research Group of Intractable Vasculitis, MHLW of Japan (1998) 9
Table 4 RCT of AAV
NORAM17WGET16CYCAZAREM15RCT
Induction of remissionMaintenance of remissionMaintenance of remissionAims
CYC vs. MTXEtanercept (Eta) vs. placebo 
(Pla)
CYC vs. AZA
Early non-renal mild AAV (n＝95)WG (n＝180)Generalized AAV (n＝155)Patients
WG: 89, MPA: 6Generalized: 128, localized: 52WG: 95, MPA: 60
Randomize either CYC (n＝
46) or MTX (n＝ 49); al re-
ceived standard corticosteroids, 
and folow-up for 18 months
Randomize either Eta (n＝89) 
or pla (n＝ 91); al received 
standard regimen, and folow-
up for 27 months
Randomize either CYC (n＝
73) or AZA (n＝ 71) after in-
duction by standard regimen, 
and folow-up for 12 months
Protocols
Results
MTX: 90%, CYC: 94% (NS)91%
(Eta: 90%, Pla: 92%) (NS)
93%・Rates of induction of re-
mission
MTX: 70%, CYC: 47% (P＝
0.02)
Eta: 66/100Pt＊year, 
Pla: 74/100Pt＊year (NS)
AZA: 16%, CYC 14% (NS)
WG: 18%, CYC: 8% (P ＝
0.03)
・Rates of relapse
MTX: 9 cases, CYC: 6 cases 
(NS)
Eta: 56%, Pla: 57% (NS)
Malignancy (Eta: 6, Pla: 0)
AZA: 11%, CYC 10% (NS)・Severe adverse efects
4 (MTX: 2, CYC: 2)6 (Eta: 4, Pla: 2)8 (7 during the first 3 months)・Death
NS: not significant
regimen: glucocorticoids plus cyclophosphamide in
generalized WG or glucocorticoids plus methotrexate
in limited WG.
At a mean follow-up of 27 months, the two groups
did not differ in their rates of sustained remission (ap-
proximately 72%), time to sustained remission, risk of
disease flares, or rates of prolonged periods of de-
creased disease activity. There was a high rate of
complications among all patients (56% to 57% in both
groups), and only 50% of the patients achieved and
maintained remissions throughout the trial. In addi-
tion to lack of efficacy, etanercept was associated with
a significantly higher number of solid tumors (six vs.
zero for placebo).18 Thus, etanercept was ineffective
for the maintenance of disease remission in
Wegener’s granulomatosis, and considering its in-
creased risk of malignancy, should not be used for
the treatment of WG.
NORAM
This European RCT compared methotrexate and cy-
clophosphamide for both induction and maintenance
ANCA-associated Vasculitis
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of remission of AAV without significant renal involve-
ment.17 The exclusion criteria were signs of poten-
tially severe systemic disease as manifested by serum
creatinine level >1.7 mgdL, red blood cell casts, se-
vere hemoptysis, cerebral infarction due to vasculitis,
orbital pseudotumor, or rapidly progressive neuropa-
thy. The trial enrolled 95 patients with newly diag-
nosed AAV (89 with WG and 6 with MPA), who were
assigned randomly to methotrexate (20 to 25 mg
week orally; n = 49) or cyclophosphamide (2 mgkg
day orally; n = 46); all patients received prednisolone.
Therapy was tapered gradually and withdrawn by 12
months.
At 6 months, 90% and 94% of patients in the
methotrexate and cyclophosphamide groups, respec-
tively, achieved remission, although the time to re-
mission was 2 months longer in the methotrexate
group. Among the patients who achieved remission,
the relapse rate at 18 months was significantly higher
in the methotrexate group (70%) than in the cyclo-
phosphamide group (47%; P = 0.023). There was a
higher incidence of leukopenia among those treated
with cyclophosphamide, and a higher incidence of
liver function test abnormalities among those treated
with methotrexate.
Thus, methotrexate was as effective as cyclophos-
phamide for induction of remission in patients with
non-renal mild AAV, but was associated with a signifi-
cantly higher relapse rate. Therefore, methotrexate
should probably be used only for non-renal limited
disease or for patients truly intolerant of cyclophos-
phamide.
OTHER TRIALS
The role of plasmapheresis was addressed in an RCT
(MEPEX), in which methylprednisolone and plasma
exchange were compared.19 This trial enrolled 151
patients with a new diagnosis of WG or MPA, and ne-
crotizing crescentic glomerulonephritis, who pre-
sented clinical signs of severe renal disease defined
as oliguria (<400 mLday), intention to start dialysis
within 48 h, andor serum creatinine level >5.7 mg
dL. The patients were assigned randomly to a plasma
exchange group (7 sessions in the first 2 weeks after
diagnosis) or intravenous methylprednisolone group
(1 gday for 3 days). In addition, all patients received
standard therapy with oral prednisolone (1 mgkg
day, tapered over 6 months) and cyclophosphamide
(2.5 mgkgday for 3 months) followed by azathio-
prine for maintenance. The full results of this trial
have not been published, although outcomes have
been reported for the 100 patients from whom renal
biopsy tissue was available for central analysis.19 A
benefit of plasmapheresis was observed only in the 69
patients who were on dialysis at the time of entry into
the study. At one-year follow-up, patients who re-
ceived plasmapheresis were more likely to be off di-
alysis (54%) than those who received methylpredniso-
lone (32%), but there was no significant difference in
mortality (29% vs. 21%). Although the effectiveness of
plasmapheresis thus remains to be clarified, the cur-
rently recommended indications of plasmapheresis
are concurrent anti-glomerular basement membrane
(GBM) antibodies, pulmonary hemorrhage, and pa-
tients requiring dialysis during the acute phase.20
As mentioned above, evidence-based regimens for
induction and maintenance of remission are cyclo-
phosphamide, azathioprine, and methotrexate. The
effectiveness of sulfamethoxazoletrimethoprim
( ST ) , 21 mycofenolate mofetil, 22,23 and cy-
closporine24,25 has not been proven. AAV in European
and American populations is associated predomi-
nantly with PR3-ANCA. For example, the three RCT
mentioned above included 440 patients with AAV,
among whom 374 patients (85%) had WG.15-17 This is
a striking difference from the disease prevalence in
Japan, where MPA or MPO-ANCA-associated vasculi-
tis is more common. Therefore, we must be careful
when applying the results of these RCT to Japanese
patients. In this regard, a prospective study to analyze
the effectiveness of the standard regimen for Japa-
nese patients with MPO-ANCA-associated vasculitis
is now underway by the Research Group of Intracta-
ble Vasculitis, MHLW of Japan, as described below.
THERAPEUTIC STRATEGY FOR AAV IN JA-
PAN
The therapeutic strategy for treatment of AAV re-
ported by the Research Group of Intractable Vasculi-
tis, MHLW of Japan,7-9 will be reviewed here.
TREATMENT OF MICROSCOPIC POLYANGIITIS
(MPA)
(a) Generalized MPA―severe form: This form in-
cludes MPA with multi-organ involvement (more
than two organs), a renal-pulmonary type (glomeru-
lonephritis plus either limited pulmonary hemor-
rhage or extended interstitial pneumonitis) and rap-
idly progressive glomerulonephritis (RPGN). Pa-
tients with this form of MPA are treated with a stan-
dard regimen to induce remission. This regimen con-
sists of high-dose prednisolone (0.6 to 1.0 mgkg
day) plus oral cyclophosphamide (0.5 to 2.0 mgkg
day). Intravenous methylprednisolone (0.5 to 1.0 g
day for 3 days) can be considered. Instead of oral ad-
ministration, intravenous cyclophosphamide (0.5 to
0.75 gm2, monthly) can also be considered. For the
RPGN type, anti-coagulation therapy (heparin at
10,000 unitsday or low-molecular heparin at 5,000
unitsday) and anti-platelet therapy (dipyridamole at
300 mgday) are also employed. In patients with im-
paired renal function (serum creatinine level >1.8
mgdL) or those more than 60 years old, the dose of
cyclophosphamide should be reduced to 75―50%. Re-
mission is evaluated by the BVAS, and, in general,
can be achieved within 6 months. Patients who have
Ozaki S
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attained remission receive maintenance therapy for
an additional 1 year. This includes prednisolone (5 to
10 mgday), and in most cases oral cyclophos-
phamide or azathioprine (25 to 75 mgday).7
(b) Generalized MPA―most severe form: This
form is defined as patients with either diffuse alveolar
hemorrhage, intestinal perforation, acute pancreatitis,
cerebral hemorrhage, concurrent anti-GBM antibod-
ies, or resistant severe disease. Patients with this
form of MPA are treated with plasmapheresis (2.0 to
3.0 Lday for 3 days; several sessions) together with
the standard regimen described above. After induc-
tion of remission, patients receive the same mainte-
nance therapy as the severe form for 1 year.
(c) Limited MPA―mild form: This form includes a
renal-limited type (except RPGN), a pulmonary-
limited type (except pulmonary hemorrhage), and
other mild forms. To induce remission, patients re-
ceive oral prednisolone (0.3 to 0.6 mgkgday; 15 to
30 mgday). Oral immunosuppressive agents (cyclo-
phosphamide or azathioprine; 0.5 to 1.0 mgkgday;
25 to 75 mgday) can also be considered. Mainte-
nance therapy after induction of remission is similar
to that in the generalized form.
PROSPECTIVE TRIAL FOR MPA IN JAPAN―
JMAAV TRIAL
To establish evidence for Japanese patients with
MPO-ANCA-associated vasculitis, the standard proto-
cols for MPA mentioned above have been evaluated
in a prospective, open-labeled, and multi-center man-
ner. The Research Group of Intractable Vasculitis and
that of Progressive Glomerular Disease, MHLW of Ja-
pan, organized a study group, named the Japanese
Study Group for MPO-ANCA-associated Vasculitis
(JMAAV), which included 27 centers from through-
out the country.26 In this trial, patients with newly di-
agnosed MPA were stratified into those with the se-
vere form, most severe form, or mild limited form of
the disease, as defined above. Patients received the
regimen according to the therapy protocol, and were
followed up for 18 months. The protocol for the se-
vere form is illustrated in Figure 1. The primary end
point was induction of remission, and the rates of se-
vere adverse effects, including death and end-stage
renal failure, were also evaluated. As secondary end
points, the effectiveness and safety of the standard
protocols were evaluated. Furthermore, peripheral
blood was collected from all assigned patients before
and 7 days after the start of initial treatment, and the
expression profiles of genes in peripheral blood cells
were analyzed using cDNA chips. This comprehen-
sive transcriptome analysis will reveal the key genes
associated with the onset of disease or the prediction
of remission. The enrollment of patients was com-
pleted at the end of September 2006, and 52 patients
were enrolled. The follow-up and intensive analysis of
patients are currently underway.
TREATMENT OF WEGENER’S GRANULOMATO-
SIS (WG)
(a) Generalized WG: To induce remission of this
form of WG, prednisolone (40 to 60 mgday) and cy-
clophosphamide (50 to 100 mgday) are adminis-
tered orally for 8 to 12 weeks. In cases of a renal-
pulmonary type (including pulmonary hemorrhage)
or RPGN type disease, a regimen similar to those for
generalized MPA (severe form) is employed. In pa-
tients intolerant of cyclophosphamide due to adverse
effects, azathioprine (50 to 100 mgday) or metho-
trexate (2.5 to 7.5 mgweek) is used. After induction
of remission, patients receive maintenance therapy:
tapering dose of prednisolone, which is stopped
within 8 to 12 weeks, plus cyclophosphamide (25 to
50 mgday), or prednisolone only (5 to 15 mgday)
without cyclophosphamide.8
(b) Limited WG: To induce remission of early and
active disease, prednisolone (15 to 30 mgday), cyclo-
phosphamide (25 to 75 mgday), and sulfamethoxa-
zoltrimethoprim (2 to 3 tabletsday) are adminis-
tered orally for 8 weeks. In patients intolerant of cy-
clophosphamide due to adverse effects, azathioprine
(25 to 75 mgday) or methotrexate (2.5 to 7.5 mg
week) is used. Maintenance therapy after induction
of remission is similar to that in the generalized form.
TREATMENT OF ALLERGIC GRANULOMATOUS
ANGIITIS (AGA)
Induction of remission can be achieved using corti-
costeroids. After intravenous methylprednisolone
(0.5 to 1.0 gday for 3 days), prednisolone (40 mg
day) is administered orally for 8 weeks. Prednisolone
is then tapered under careful monitoring of clinical
symptoms and laboratory findings (especially eosino-
phil counts). Patients with active angiitis can receive
cyclophosphamide or azathioprine (50 to 100 mg
day).9 Asthma is treated as usual.
NOVEL THERAPIES OF AAV
The three RCT described above15-17 yielded induction
of remission at rates of approximately 90%. Therefore,
true “cyclophosphamide resistance,” which is defined
as the presence of active disease affecting a major or-
gan despite optimal doses of daily cyclophosphamide
and corticosteroids, is rare in AAV. Clinical situations
labeled cyclophosphamide resistance are often due to
failure to distinguish correctly between active disease
and what may present with manifestations similar to
active disease, such as permanent damage, the pres-
ence of other diseases, or the development of medica-
tion toxicities (e.g., infections). These conditions
should be ruled out carefully to judge true “cyclo-
phosphamide resistance”, for which various novel
therapies have been attempted in an open-labeled
style.27
ANCA-associated Vasculitis
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Fig. 1 Protocol of standard regimen for severe form of generalized MPA. This 
protocol was used in a prospective, open-labeled, and multi-center trial for patients 
with newly diagnosed severe form of MPA performed by JMAAV.26 The“severe 
form”is defined as outlined in the text. This regimen consists of high-dose predni-
solone (0.6 to 1.0 mg/kg/day) plus oral cyclophosphamide (0.5 to 2.0 mg/kg/day). 
Intravenous methylprednisolone (0.5 to 1.0 g/day or 3 days) can be considered. In-
stead of oral administration, intravenous cyclophosphamide (0.5 to 0.75 g/m2, 
monthly) can also be considered. For the RPGN type, anti-coagulation therapy 
(heparin at 10,000 units/day or low molecular weight heparin at 5,000 units/day) 
and anti-platelet therapy (dipyridamole at 300 mg/day) are also employed. In pa-
tients with impaired renal function (serum creatinine level＞1.8 mg/dL) or those 
greater than 60 years old, the dose of cyclophosphamide should be reduced to 75
―50%. Remission is evaluated by the BVAS, and in general can be achieved within 
6 months. Patients who have achieved remission receive maintenance therapy for 
an additional year. This therapy includes prednisolone (5 to 10 mg/day), and in 
most cases together with oral cyclophosphamide or azathioprine. The primary end 
point of this prospective trial was induction of remission, and the rates of severe ad-
verse efects, including death and end-stage renal failure, were evaluated. As a 
secondary evaluation, the efectiveness and safety of the standard protocols were 
analyzed. Furthermore, peripheral blood was colected from al assigned patients 
before and 7 days after the initial treatment, and transcriptome analysis of genes in 
peripheral blood cels was performed using cDNA chips to determine key genes as-
sociated with the onset of disease or the prediction of remission.
Maintenance of remissionInduction of remission
mPSL-pulse(0.5―1 g/day)×3days
PSL
IV-CYC (0.5―0.75g/m2)
oral CYC or AZA
0 6 months
(10―5 mg/day) 
(0.6―1 mg/kg/day)
oral CYC(0.5―2 mg/kg/day)
or
Transcriptome analysis
(Days 0 and 7)
18 months
and
/or
BIOLOGICAL AGENTS
(a) TNF blockers: Biological agents to block tumor
necrosis factor (TNF) alpha include etanercept (En-
brel; soluble receptors), infliximab (Remicade;
human-mouse chimeric antibody against TNF), and
adalimumab (Humila; human anti-TNF antibody).
Among these, etanercept was of no additional effec-
tiveness in maintenance of remission and appeared to
be associated with a risk of malignancy, as described
above.16,18 At present, no data are available on the use
of adalimumab, and only limited data are available re-
garding the efficacy of infliximab in AAV. In an open
label study, infliximab was administered to 32 pa-
tients.28 Infliximab (5 mgkg, 4 times at weeks 0, 2, 6,
and 10) was administered in combination with exist-
ing immunosuppressive agents. Twenty-eight pa-
tients (88%) achieved remission within a mean of 6.4
weeks. Serious infections and death were reported in
seven and two patients, respectively, while five pa-
tients had a relapse at a mean of 27 weeks.
(b) Anti-B-cell therapy: It has been suggested that
elimination of B lymphocytes with anti-CD20 anti-
body (rituximab) might have a favorable effect on
Wegener’s granulomatosis by removing the cells re-
sponsible for producing ANCA.
Rituximab and high-dose glucocorticoids appeared
to be of benefit in a study of 11 patients with refrac-
tory AAV.29 All patients had refractory disease de-
fined as persistent active disease despite maximally
tolerated cyclophosphamide, or a contraindication to
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cyclophosphamide therapy. The protocol consisted of
high-dose corticosteroids plus four weekly infusions
of rituximab (375 mgm2), with three patients also
undergoing plasma exchange. Remission was
achieved in all patients, with rituximab being toler-
ated well. This response was associated with elimina-
tion of circulating B lymphocytes, and a decrease in
ANCA titer. Remission was maintained during the pe-
riod in which B lymphocytes remained absent.
The potential benefit of rituximab in treating dis-
ease manifestations that are typically not improved by
standard immunosuppressive regimens (subglottic
stenosis and retrobulbar granulomas) has also been
examined. In a preliminary study, eight patients (5
with retrobulbar and 1 with pulmonarysinus granu-
loma, and 2 with subglottic stenosis), who had not re-
sponded to conventional immunosuppression and
anti-TNF antibody therapy, were treated with four
weekly infusions of rituximab (375 mgm2).30 Im-
provement of disease manifestations was noted in the
patient with pulmonarysinus granuloma and in one
of the patients with subglottic stenosis, but in none of
the patients with retrobulbar disease.
Further studies of rituximab in patients with WG
andor MPA are needed to better understand its ef-
fectiveness, and whether the development of antibod-
ies limits its long-term usefulness; a randomized
double-blind trial (RAVE) is currently underway.27
(c) Anti-T-cell therapy: The observation that active
systemic vasculitis is mediated in part by T cell-
induced injury has led to the evaluation of anti-T cell
antibodies in patients with WG who are resistant to or
cannot tolerate cyclophosphamide.
In one study, the administration of a combination
of two humanized monoclonal antibodies (one di-
rected against CAMPATH-1H, an antigen on all
mononuclear cells, and one directed against CD4) led
to long-lasting remission in 4 patients with different
forms of refractory vasculitis.31 This was also accom-
panied by toxicity that included infusion reactions, in-
fection, autoimmune events, and prolonged lympho-
cyte depletion.
Among 15 patients with refractory disease, anti-
thymocyte globulin (ATG) resulted in partial or com-
plete remission in 9 and 4 patients, respectively.32
However, 2 patients died 1 and 3 days after the first
administration of ATG (due to pulmonary hemor-
rhage and infection). The role of these experimental
therapies remains to be determined.
INTRAVENOUS IMMUNOGLOBULIN (IVIG)
IVIG has been studied in only a limited fashion in
AAV, and none of the available studies provide clear
answers regarding its potential efficacy in this dis-
ease. One randomized, placebo-controlled study of 34
patients with AAV found that IVIG (2 gkg) was asso-
ciated with a transient improvement in constitutional
symptoms, arthralgia, and ENT manifestations.33 Im-
provement occurred in only 6 of 13 patients who had
lung involvement, but no information was provided
regarding the presence or response of renal manifes-
tations of the disease. A Japanese group treated 30
patients with MPA (RPGN type), who were positive
for MPO-ANCA, with a standard regimen plus IVIG
(2 gkg), and found decreased levels of C-reactive
protein and the avoidance of new end-stage renal fail-
ure.34 To date, the uncertainty regarding the efficacy
of IVIG has led many investigators to be hesitant
about its use in systemic vasculitides other than
Kawasaki disease.27
OTHERS
Other novel therapies include etoposide,35 15-
deoxyspergualin,36,37 intravenous azathioprine,38 ra-
diation therapy,39,40 and high-dose myeloablative che-
motherapy with stem cell transplantation.41 Most of
these methods, however, are associated with strong
adverse effects. In the absence of further data, these
experimental therapies should not be used for the
treatment of WG or other forms of AAV.
CONCLUSIONS
In conclusion, AAV is one of the best investigated
vasculitides, and the clinical significance of ANCA
has been clearly demonstrated. A therapeutic strat-
egy has been established, and global evidence has
been accumulated by several RCT. Most of these
studies, however, have dealt with patients with PR3-
ANCA-associated disease, whereas most patients in
Japan are associated with MPO-ANCA. Although the
evidence for these Japanese patients remains to be
established, the prospective, open-labeled, and multi-
center trial currently underway by JMAAV will clarify
the effectiveness and safety of the standard therapeu-
tic regimen in the near future.
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